Videos

Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC

June 30, 2022

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.